GT Medical Technologies announced the completion of an oversubscribed $100 million Series E financing round led by new investor Viking Global Investors, with participation from existing investors including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures.
The company said the proceeds will support commercial and operational expansion following the release of final data from its ROADS randomized controlled trial and will also fund continued development of its BRIDGES clinical trial for newly diagnosed glioblastoma patients.
GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiotherapy implant designed for patients with operable brain tumors. The therapy is placed during tumor removal surgery and delivers immediate targeted radiation to the tumor resection site, eliminating the delay typically required before conventional radiation treatment can begin.
According to data from the Phase 3 ROADS trial, which was presented at the 2026 American Society of Clinical Oncology conference, GammaTile demonstrated statistical superiority compared with standard treatment in patients with newly diagnosed brain metastases. The study found that GammaTile reduced the risk of tumor recurrence and death at 12 months by 93% and 41%, respectively.
The data also showed that the 12-month surgical bed recurrence rate was 1.3% for GammaTile-treated patients compared with 15.4% for those receiving standard care. Median surgical bed recurrence-free survival had not yet been reached for GammaTile recipients, compared with 10.9 months for standard treatment. In addition, 24-month overall survival was 61.7% for GammaTile patients versus 35.7% for those receiving standard care.
GT Medical Technologies said the financing provides flexibility to accelerate growth and make additional investments in clinical and operational capabilities.
Founded by a team of tumor specialists, GT Medical Technologies is focused on developing technologies intended to improve outcomes for patients with brain tumors.
KEY QUOTES:
“This financing is validation of GammaTile’s potential to be a standard of care treatment for operable brain tumors and will accelerate our ability to bring this important therapy to even more patients.”
Per Langoe, Chief Executive Officer, GT Medical Technologies
“We are excited to lead this financing and to work with GT to unlock the potential of GammaTile therapy. GT Medical Technologies’ technology has demonstrated profound clinical impact, and we look forward to supporting the GT Medical Technologies team in improving the treatment algorithm for patients with resectable brain tumors.”
Jason Rostovsky, Principal, Viking Global Investors
“An oversubscribed financing of this magnitude and the strength of our syndicate provides significant optionality for the Company, allowing us to accelerate the next phase of our growth and make meaningful clinical and operational investments for the future.”
James Leech, Chief Financial & Strategy Officer, GT Medical Technologies
